VanEck Associates
URGN icon

VanEck Associates’s UroGen Pharma URGN Stock Holding History

VanEck Associates’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,829
Closed -$94K – 1319
2021
Q1 		$94K Buy
4,829
+71
+1% +$1.51K ﹤0.01% 1012
2020
Q4 		$86K Sell
4,758
-998
-17% -$20.9K ﹤0.01% 925
2020
Q3 		$111K Buy
5,756
+119
+2% +$2.69K ﹤0.01% 876
2020
Q2 		$147K Sell
5,637
-177
-3% -$4.33K ﹤0.01% 828
2020
Q1 		$104K Buy
5,814
+198
+4% +$5.35K ﹤0.01% 824
2019
Q4 		$187K Sell
5,616
-216
-4% -$5.9K ﹤0.01% 825
2019
Q3 		$139K Buy
5,832
+19
+0.3% +$621 ﹤0.01% 738
2019
Q2 		$209K Buy
5,813
+1,345
+30% +$49.6K ﹤0.01% 715
2019
Q1 		$165K Buy
4,468
+104
+2% +$4.36K ﹤0.01% 728
2018
Q4 		$188K Buy
4,364
+944
+28% +$42.4K ﹤0.01% 708
2018
Q3 		$162K Buy
3,420
+196
+6% +$9.11K ﹤0.01% 726
2018
Q2 		$160K Buy
3,224
+198
+7% +$11.5K ﹤0.01% 731
2018
Q1 		$150K Buy
3,026
+202
+7% +$10.1K ﹤0.01% 622
2017
Q4 		$105K Buy
+2,824
New +$101K ﹤0.01% 628

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VanEck Associates's URGN Position: Q2 2021 in Review

VanEck Associates sold out of UroGen Pharma (URGN) in Q2 2021, closing a stake of 4,829 shares — an estimated $94K sold.

VanEck Associates first reported a position in URGN in Q4 2017 and held it in 14 quarters. The position peaked at $209K in Q2 2019. 82 funds tracked by Wall St. Rank hold URGN as of Q2 2021.

  • VanEck Associates reported no remaining UroGen Pharma position as of Q2 2021 after selling out during the quarter.
  • VanEck Associates sold 4,829 UroGen Pharma shares in Q2 2021, an estimated $94K.
  • VanEck Associates first reported a position in UroGen Pharma in Q4 2017 and held it in 14 quarters.
  • VanEck Associates's UroGen Pharma position peaked at $209K in Q2 2019.
  • 82 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2021.

Based on VanEck Associates's 13F filing for Q2 2021, filed 10 Aug 2021.